Clinical trials: Chronic Cutaneous Lupus Erythematosus
Discoid Lupus
A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus
The purpose of the study is to assess if CC-930 is safe and tolerable in treating subjects with Discoid Lupus Erythematosus. Pharmacokinetic and pharmacodynamics will also be evaluated.
- Trial name
- NCT01466725
- Testing
- CC-930
- Where
- 19 sites in United States
- Volunteers
- 5 people
- Sponsor
- Celgene
Discoid Lupus Erythematosus
A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing.
- Trial name
- NCT00001680
- Testing
- Thalidomide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Cutaneous Lupus Erythematosus
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Primary Objective: Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity)…
- Trial name
- CLEan (NCT04781816)
- Testing
- SAR443122
- Where
- 50 sites in United States, Argentina and 13 more
- Volunteers
- 78 people
- Sponsor
- Sanofi
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid
Cutaneous Lupus Erythematosus and Elidel
This trial evaluates the therapeutic effect of Elidel (pimecrolimus) in comparison to the corresponding vehicle in patients with chronic discoid lupus erythematosus (dLE) or subacute cutaneous lupus erythematosus (scLE).
- Trial name
- NCT00222183
- Testing
- Elidel (pimecrolimus)
- Where
- Germany
- Sponsor
- University of Leipzig
Discoid Lupus Erythematosus (DLE)
The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus
A 20 week study to assess the safety and efficacy of etanercept(Enbrel®)for the treatment of Discoid Lupus Erythematosus
- Trial name
- DISCLUP2008 (NCT00797784)
- Testing
- etanercept(Enbrel®)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Discoid Lupus Erythematosus
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.
- Trial name
- NCT06261021
- Testing
- Ruxolitinib 1.5% cream, Application without occlusion in Area 1, Application under occlusion at night in Area 2
- Where
- 2 sites in Canada
- Volunteers
- 20 people
- Sponsor
- Innovaderm Research Inc.
Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous
Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus
The purpose of this study is to determine whether Etanercept which is given through intradermal injection is effective in the treatment of discoid lupus erythematosus (DLE).
- Conditions
- Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous
- Trial name
- TARGET-DLE (NCT02656082)
- Testing
- Etanercept
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- University of Leeds
Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic…
- Trial name
- ELOWEN-1 (NCT07332481)
- Testing
- Enpatoran, Standard of care (SoC)
- Where
- 60 sites in United States, Australia and 14 more
- Volunteers
- 202 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Discoid Lupus Erythematosus
Study of Daxdilimab (HZN-7734) in Participants With Moderate-to-Severe Primary Discoid Lupus Erythematosus
A Phase 2, double-blind, randomized, placebo-controlled parallel-group study to evaluate the efficacy and safety of daxdilimab in participants with moderate-to-severe active primary Discoid Lupus Erythematosus (DLE) refractory to…
- Trial name
- NCT05591222
- Testing
- Daxdilimab
- Where
- 68 sites in United States, Argentina and 9 more
- Volunteers
- 72 people
- Sponsor
- Amgen
Discoid Lupus Erythematosus
A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus
Discoid lupus erythematosus is a chronic inflammatory skin condition and may lead to itch, skin pain, open sores, scarring, disfigurement and hair loss.
- Trial name
- NCT03866317
- Testing
- Secukinumab
- Where
- United States
- Sponsor
- Massachusetts General Hospital
Discoid Lupus Erthematosus of the Scalp
Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva
The purpose of this study is to investigate the efficacy of Raptiva (efalizumab) in the treatment of discoid lupus erythematosus (DLE).
- Trial name
- NCT00308204
- Testing
- Raptiva
- Where
- United States
- Sponsor
- The Cleveland Clinic
Cutaneous Lupus Erythematosus (CLE)
Lenalidomide vs Methotrexate in Difficult-to-treat Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is a heterogeneous inflammatory autoimmune disease associated or not with systemic lupus erythematosus (SLE).
- Trial name
- LEISURE (NCT06965244)
- Testing
- Lenalidomide, Methotrexate (MTX)
- Volunteers
- 122 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.
- Trial name
- NCT06980805
- Testing
- IMVT-1402
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 56 people
- Sponsor
- Immunovant Sciences GmbH
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called BIIB059 (litifilimab) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST LTE (NCT06044337)
- Testing
- BIIB059 (litifilimab)
- Where
- 104 sites in United States, Argentina and 23 more
- Volunteers
- 306 people
- Sponsor
- Biogen
Lupus Erythematosus, Cutaneous
Efficacy and Safety of Oral Alitretinoin (Toctino®) in the Treatment of Patients With Cutaneous Lupus Erythematosus
To evaluate the therapeutic effect of oral alitretinoin (Toctino®) in the treatment of CLE with respect to proportion of responders based on the Revised Cutaneous Lupus Disease Area and Severity Index (RCLASI) activity score for…
- Trial name
- AliCLE (NCT01407679)
- Testing
- Alitretinoin
- Where
- 3 sites in Germany
- Volunteers
- 7 people
- Sponsor
- University Hospital Muenster
Lupus
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection…
- Trial name
- NCT06013995
- Testing
- BMS-986326
- Where
- 20 sites in United States, Argentina and 6 more
- Volunteers
- 45 people
- Sponsor
- Bristol-Myers Squibb
Atopic Dermatitis, Psoriasis
Determinants of Chronic Inflammatory Skin Disease Trajectories
Although it is well known that the clinical expression and course of chronic inflammatory skin diseases are highly variable, there are insufficient epidemiological data on this, and the factors that determine the manifestation…
- Conditions
- Atopic Dermatitis, Psoriasis, Lichen Planus, Alopecia Areata
- Trial name
- NCT05928169
- Testing
- Topical and systemic drugs
- Where
- Germany
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- University Hospital Schleswig-Holstein
Cutaneous Lupus Erythematosus
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
This study aims to evaluate the efficacy and safety of subcutaneous (SC) anifrolumab versus placebo in adult participants with chronic and/or subacute cutaneous lupus erythematosus (CLE).
- Trial name
- LAVENDER (NCT06015737)
- Testing
- Anifrolumab
- Where
- 188 sites in United States, Argentina and 30 more
- Volunteers
- 339 people
- Sponsor
- AstraZeneca
Discoid Lupus Erythematosus
Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.
This was a double-blind, multi-centre, randomised, vehicle-controlled, within-subject phase 2a trial. The trial was designed to establish the efficacy and safety of delgocitinib cream in the treatment of adult subjects with…
- Trial name
- NCT03958955
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 19 sites in United States, Denmark and 2 more
- Volunteers
- 27 people
- Sponsor
- LEO Pharma
Discoid Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid…
- Trial name
- NCT07557927
- Testing
- Dihydroartemisinin tablets, Hydroxychloroquine tablets
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Kunming Pharmaceuticals, Inc.